Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07323654 · ClinicalTrials.gov registry record · Phase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
A Phase 2 study of Eosinophilic Asthma, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
- 9
- Study locations
NCT07323654: Recruiting Phase 2 study of Eosinophilic Asthma, sponsored by Kymera Therapeutics.
NCT07323654 is a Phase 2 study of Eosinophilic Asthma that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 264 participants, below the 506-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07323654, a Phase 2 study of Eosinophilic Asthma, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG KT-621
Study Locations (9)
Florida
- Kymera Investigative Site - Miami
- Kymera Investigative Site - Tampa
California
- Kymera Investigative Site - Upland
Georgia
- Kymera Investigative Site - East Point
Oklahoma
- Kymera Investigative Site - Edmond
Oregon
- Kymera Investigative Site - Clackamas
Pennsylvania
- Kymera Investigative Site - Pittsburgh
South Carolina
- Kymera Investigative Site - North Charleston
Tennessee
- Kymera Investigative Site - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT07323654 shows while recruiting
NCT07323654 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 506-participant average among 4 other Eosinophilic Asthma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Eosinophilic Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07323654 lists 9 locations in 8 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT07323654 about?
NCT07323654 is a clinical study titled "A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma". This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety...
What is the current status of trial NCT07323654?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2026-01-28. Estimated completion is 2027-12.
What conditions does trial NCT07323654 study?
This clinical trial studies the following conditions: Eosinophilic Asthma.
What interventions are being tested in trial NCT07323654?
The interventions under investigation include: Placebo (OTHER), KT-621 (DRUG).
Who is sponsoring clinical trial NCT07323654?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07323654 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Oklahoma, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
COMPLETED · Phase 2
-
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
RECRUITING · Phase 3
-
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI